Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer

Expert Opinion on Investigational Drugs

Volumn 20, Issue 6, 2011, Pages 769-778

  Liu, Stephen V ^a   Liu, Shanshan ^a   Pinski, Jacek ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

AN 152; LHRH receptor; prostate cancer; targeted therapy

Indexed keywords

5 [(3,5,5,8,8 PENTAMETHYL 5,6,7,8 TETRAHYDRO 2 NAPHTHALENYL)METHYL] N (2,4,6 TRIMETHOXYPHENYL) 2 FURAMIDE; ABARELIX; AJ 04; ANALOG 1; CETRORELIX; DEGARELIX; DESLORELIN; DESLORELIN DOCETAXEL; DOCETAXEL; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GONADORELIN HECATE; GONADORELIN POKEWEED ANTIVIRUS PROTEIN CONJUGATE; GONADORELIN RECEPTOR; GONADORELIN[1,3 (N ACETYL DEXTRO TRYPTOPHAN) 2 (4 CHLORO DEXTRO PHENYLALANINE) 6 DEXTRO LYSINE 10 DEXTRO ALANINE]; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; JC21LHRH; JCHLHRH; LEUPRORELIN; MAYTANSINE; MIS 1544; PEPTIDE DERIVATIVE; POKEWEED ANTIVIRUS PROTEIN; T 98; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL (TOPIC); DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; HUMAN; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, LHRH;

EID: 79955866326     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.574611     Document Type: Review

References (83)

1. Jemel A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
2. Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 2004;15(7):300-10 (Pubitemid 39193184)
3. Tolis G, Ackman D, Stellos A, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. PNAS 1982;79(5):l658-62
4. Vickery BH. Comparison of the potential for therapeutic utilities with gonadotropin-releasing hormone agonists and antagonists. Endocr Res 1986;7:115
5. Weinbauer GF, Nieschlag E. LH-RH antagonists: state of the art and future perspectives. Recent Results Cancer Res 1992;124:113-36
6. Hoffken K. LH-RH agonists in the treatment of premenopausal patients with advanced breast cancer. Recent Results Cancer Res 1992;24:91
7. Scott WW, Menon M, Walsh PC. Hormonal therapy of prostate cancer. Cancer 1980;45:1929
8. Ross RW, Xie W, Regan MM, et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer. Cancer 2008;112:1247-53
9. Volker P, Grundker C, Schmidt O, et al. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogs. Am J Obstet Gynecol 2002;186:171-9 (Pubitemid 34165428)
10. Imai A, Ohno T, Iida K, et al. Presence of gonadotropin-releasing hormone receptor and its messenger ribonucleic acid in endometrial carcinoma and endometrium. Gynecol Oncol 1994;55(l):144-8
11. Friess H, Buchler M, Kiesel L, et al. LH-RH receptors in the human pancrease. Basis for anti-hormonal treatment in ductal carcinoma of the pancrease. Int J Pancreatol 1991;10:151-9
12. Ben-Yehudah A, Lorberboum-Galski H. Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteins. Expert Rev Anti Cancer Ther 2004;4:151-61 (Pubitemid 38208494)
13. Sion-Vardi N, Kaneti J, Segal-Abramson T, et al. Gonadotropin-releasing hormone specific binding sites in normal and malignant renal tissue. J Urol 1992;148:1568-70
14. Bahk JY, Kim MO, Park MS, et al. Gonadotropin-releasing hormone (GnRH) and GnRH receptor in bladder cancer epithelia and GnRH effect on bladder cancer cell proliferation. Urol Int 2008;80(4):431-8 (Pubitemid 351915032)
15. Baumann KH, Kiesel L, Kaufmann M, et al. Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Res Treat 1993;25:37-46 (Pubitemid 23107734)
16. Schally AV, Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 2003;72:2305-20 (Pubitemid 36287676)
17. Nagy A, Schally AV. Cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH); a new approach to targeted chemotherapy. Drugs Future 2002;27:359-70 (Pubitemid 34639718)
18. Halmos G, Arencibia JM, Schally AV, et al. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 2000;163:623-9 (Pubitemid 30060537)
19. Straub B, Muller M, Krause H, et al. Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone refractory human prostate cancers. Clin Cancer Res 2001;7:2340-3 (Pubitemid 32751633)
20. Straub B, Muller M, Krause H, et al. Real-time quantitative reverse transcriptase-polymerase chain reaction for luteinizing hormone-releasing hormone receptor gene mRNA expression in human prostate cancer. Urology 2003;62:172-6 (Pubitemid 36802109)
21. Szabo J, Vegh A, Racz G, Szende B. Immunohistochemical demonstration of gonadotropin-releasing hormone receptors in prostate carcinoma. Urol Oncol 2005;23(6):399-401 (Pubitemid 41654505)
22. Schally AV, Comaru-Schally AM. Hypothalamic and other peptide hormones. In: Kufe DW, et al., editors, Cancer medicine. BC Decker; 2003. p. 911-26
23. Stojilkovic SS, Catt KJ. Expression and signal transduction pathways of gonadotropin releasing hormone receptors. Rec Prog Horm Res 1995;50:161-205
24. Limonta P, Dondi D, Moretti RM, et al. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1992;75(1):207-12
25. Dondi D, Limonta P, Moretti RM, et al. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 1994;54(15):4091-5 (Pubitemid 24258114)
26. Dondi D, Moretti RM, Montagnani Marelli M, et al. Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice. Int J Cancer 1998;76(4):506-11 (Pubitemid 28227993)
27. Srkalovic G, Bokser L, Radulovic S, et al. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75. Endocrinology 1990;127:3052-60
28. Liu SV, Schally AV, Hawes D, et al. Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists. Clin Cancer Res 2010;l6(18):4675-80
29. Grundker C, Volker P, Griesinger F, et al. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol 2002;187:528-37
30. Moreau JP, Delavault P, Blumberg J. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy. Clin Ther 2006;28(10):1485-508 (Pubitemid 44841984)
31. Katsila T, Balafas E, Liapakis G, et al. Evaluation of a stable gonadotropin releasing hormone analogue in mice for the treatment of endocrine disorders and prostate cancer. J Pharmacol Exp Ther 2010;336:613-23
32. Lawrentschuk N, Fernandes K, Bell D, et al. Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. J Urol 2011;185:848-54
33. Kirby RS, Fitzpatrick JM, Clarke N. Abarelix and other gonadotropin-releasing hormone antagonists in prostate cancer. BJU Int 2009;104(11):1580-4
34. Beer TM, Ryan C, Bhat G, Garnick M. Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study. Anticancer Drugs 2006;17(9):1075-9 (Pubitemid 44454785)
35. Beer TM, Garzotto M, Eilers KM, Lemmon D. Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy. J Urol 2003;l69(5):1738-41 (Pubitemid 36443484)
36. McLeod D, Zinner N, Tomera K, et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001;58:756-61
37. Van Poppel H, Tombal B, de la Rosette JM, et al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) blocker-results from a one-year, multicentre, randomised, phase 2 dose-finding study in the treatment of prostate cancer. Eur Urol 2008;54:805-15
38. Debruyne F, Bhat G, Garnick MB. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncol 2006;2:677-96 (Pubitemid 44941986)
39. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102(11):1531-8
40. Kovacs M, Schally AV. Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats. PNAS 2001;98:12197-202 (Pubitemid 32959850)
41. Pommerville PJ, de Boer JG. GnRH antagonists in the treatment of advanced prostate cancer. Can J Urol 2010;17:5063-70
42. Schally AV. New approaches to the therapy of various tumors based on peptide analogues. Horm Metab Res 2008;40:315-22 (Pubitemid 351859442)
43. Anderes KL, Luthin DR, Castillo R, et al. Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats. J Pharmacol Exp Ther 2003;305(2):688-95 (Pubitemid 36459188)
44. Kovacs M, Mezo I, Seprodi J, et al. Effects of long-term administration of a superactive agonistic and an antagonistic GnRH analog on the pituitary-go nad system. Peptides 1989;10:925
45. Palyi I, Vincze B, Lovas S, et al. Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity. PNAS 1999;96:2361-6 (Pubitemid 29117920)
46. Kalnay A, Palyi I, Vincze B, et al. Influence on antiproliferative activity of structural modification and conjugation of gonadotropin-releasing hormone (GnRH) analogues. Cell Prolif 2000;33:275-85
47. Leuschner C, Hansel W. Membrane disrupting lytic peptides for cancer treatments. Curr Pliarm Des 2004;10:2299-310 (Pubitemid 38855038)
48. Arlotti JA, Cimino TS, Nguyen T, et al. Efficacy of a synthetic lytic peptide in the treatment of prostate cancer. Urol Oncol 2001;6:97-102 (Pubitemid 32409994)
49. Hansel W, Leuschner C, Gawronska B, Enright F. Targeted destruction of prostate cancer cells and xenografts by lytic peptide-beta LH conjugates. Reprod Biol 2001;1:20-32
50. Hansel W, Leuschner C, Enright F. Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases. Mol Cell Endocrinol 2007;269:26-33 (Pubitemid 46483829)
51. Leuschner C, Enright FM, Gawronska-Kozak B, Hansel W. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors. Prostate 2003;56:239-49 (Pubitemid 36988744)
52. Yates C, Sharp S, Jones J, et al. LHRH-conjugated lytic peptides directly target prostate cancer cells. Biochem Pharmacol 2011;81:104-10
53. Deng X, Klussmann S, Wu GM, et al. Effect of LHRH-PE40 on target cells via LHRH receptors. J Drug Target 2008;l6(5):379-88 (Pubitemid 351935735)
54. Nechushtan A, Yarkoni S, Marianovsky I, Lorberboum-Galski H. Adenocarcinoma cells are targeted by the new GnRH-PE66 chimeric toxin through specific gonadotropin-releasing hormone binding sites. J Biol Chem 1997;272(17):597-603
55. Irvin JD, Uckun FM. Pokeweed antiviral protein: ribosome inactivation and therapeutic applications. Pharmacol Ther 1992;55:279-302 (Pubitemid 23031374)
56. Hartley MR, Legname G, Osborn R, et al. Single-chain ribosome inactivating proteins from plants depurinate Escherichia coli 23S ribosomal RNA. FEBS Lett 1991;290:65-8
57. Hudak KA, Dinman JD, Turner NE. Pokeweed antiviral protein accesses ribosomes by binding to L3. J Biol Chem 1999;274(6):3859-64 (Pubitemid 29077236)
58. Schlick JL, Dulieu P, Desvoyes B, et al. Cytotoxic activity of a recombinant GnRH-PAP fusion toxin on human tumor cell lines. FEBS Lett 2000;472:241-6 (Pubitemid 30224472)
59. Yang WH, Wieczorck M, Allen MC, Nett TM. Cytotoxic activity of gonadotropin-releasing hormone (GnRH)-pokeweed antiviral protein conjugates in cell lines expressing GnRH receptors. Endocrinology 2003;144:1456-63 (Pubitemid 36428487)
60. Azar Y, Lorberboum-Galski H. GnRH-Bik/Bax/Bak chimeric proteins target and kill adenocarcinoma cells; the general use of pro-apoptotic proteins of the Bcl-2 family as novel killing components of targeting chimeric proteins. Apoptosis 2000;5(6):531-42 (Pubitemid 32182551)
61. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999;141:1-14 (Pubitemid 29370830)
62. Bajusz S, Janaky T, Csernus VJ, et al. Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6. PNAS 1989;86:6318-22 (Pubitemid 19210643)
63. Bajusz S, Janaky T, Csernus VJ, et al. Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. PNAS 1989;86:6313-17 (Pubitemid 19210642)
64. Pinski J, Schally AV, Yano T, et al. Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals. Prostate 1993;23:165-78 (Pubitemid 23289897)
65. Emons G, Sindermann H, Engel J, et al. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. Neuroendocrinology 2009;90:15-18
66. Nagy A, Schally AV, Armatis P, et al. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. PNAS 1996;93(l4):7269-73 (Pubitemid 26243538)
67. Westphalen S, Kotulla G, Kaiser F, et al. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncol 2000;17:1063-9
68. Gunthert AR, Grundker C, Bongertz T, et al. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system. Am J Obstet Gynecol 2004;191(4):1164-72 (Pubitemid 39421567)
69. Gunthert AR, Grundker C, Bongertz T, et al. Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH) in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system. Breast Cancer Res Treat 2004;87:255-64 (Pubitemid 39505942)
70. Reile H, Birnbock H, Bernhardt G, et al. Computerized determination of growth kinetic curves and doubling times from cells in microculture. Anal Biochem 1990;187(2):262-7 (Pubitemid 20183465)
71. Letsch M, Schally AV, Szepeshazi K, et al. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Clin Cancer Res 2003;9:4505-13 (Pubitemid 37248409)
72. De Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;l4(19):6302-9
73. Kovacs M, Schally AV, Csernus B, et al. Targeted cytotoxic analogue of luteinizing hormone-releasing hormone (LH-RH) only transiently decreases the gene expression of pituitary receptors for LH-RH. J Neuroendocrinol 2002;14:5-13 (Pubitemid 34083065)
74. Kovacs M, Schally AV, Nagy A, et al. Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone. PNAS 1997;94(4):l420-5
75. Emons G, Kaufmann M, Gorchev G, et al. Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. Gynecol Oncol 2010;119:457-61
76. Emons G, Tomov S, Harter P, et al. Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor-positive platinum resistant ovarian cancer. JCO 2010;28(15S):abstract 5035
77. Nagy A, Armatis P, Schally AV. High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin. PNAS 1996;93:2464-9
78. Koppan M, Nagy A, Schally AV, et al. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. Prostate 1999;38:151-8 (Pubitemid 29052954)
79. Jungwirth A, Schally AV, Nagy A, et al. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. Int J Oncol 1997;10:877-84 (Pubitemid 27210149)
80. Sundaram S, Durairaj C, Kadam R, Kompella UB. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy. Mol Cancer Ther 2009;8(6):1655-65
81. Tannock IF, de Wit R, Berry WR, et al.; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. NEJM 2004;351:1502-12 (Pubitemid 39315317)
82. Junutula JR, Flagella KM, Graham RA, et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 2010;16(19):4769-78
83. Burris HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. JCO 2011;29:398-405